MC
MGNX icon

Muhlenkamp & Co’s MacroGenics MGNX Stock Holding History

Muhlenkamp & Co’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,515
Closed -$200K – 56
2017
Q4 		$200K Sell
10,515
-2,237
-18% -$41.8K 0.06% 69
2017
Q3 		$236K Sell
12,752
-415
-3% -$7.19K 0.07% 66
2017
Q2 		$231K Hold
13,167
– – 0.07% 67
2017
Q1 		$245K Buy
13,167
+364
+3% +$7.02K 0.08% 71
2016
Q4 		$262K Buy
12,803
+641
+5% +$16.1K 0.08% 68
2016
Q3 		$364K Sell
12,162
-3,673
-23% -$109K 0.14% 45
2016
Q2 		$427K Sell
15,835
-51,410
-76% -$1.16M 0.17% 41
2016
Q1 		$1.26M Buy
67,245
+835
+1% +$15.9K 0.51% 29
2015
Q4 		$2.06M Sell
66,410
-90
-0.1% -$2.73K 0.62% 29
2015
Q3 		$1.42M Hold
66,500
– – 0.42% 34
2015
Q2 		$2.52M Buy
66,500
+95
+0.1% +$3.12K 0.55% 35
2015
Q1 		$2.08M Buy
66,405
+49,680
+297% +$1.68M 0.44% 38
2014
Q4 		$587K Sell
16,725
-250
-1% -$6.23K 0.12% 52
2014
Q3 		$355K Buy
+16,975
New +$351K 0.06% 57

Other funds holding MGNX

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Muhlenkamp & Co's MGNX Position: Q1 2018 in Review

Muhlenkamp & Co sold out of MacroGenics (MGNX) in Q1 2018, closing a stake of 10,515 shares — an estimated $200K sold.

Muhlenkamp & Co first reported a position in MGNX in Q3 2014 and held it in 14 quarters. The position peaked at $2.52M in Q2 2015. 132 funds tracked by Wall St. Rank hold MGNX as of Q1 2018.

  • Muhlenkamp & Co reported no remaining MacroGenics position as of Q1 2018 after selling out during the quarter.
  • Muhlenkamp & Co sold 10,515 MacroGenics shares in Q1 2018, an estimated $200K.
  • Muhlenkamp & Co first reported a position in MacroGenics in Q3 2014 and held it in 14 quarters.
  • Muhlenkamp & Co's MacroGenics position peaked at $2.52M in Q2 2015.
  • 132 funds tracked by Wall St. Rank held MacroGenics as of Q1 2018.

Based on Muhlenkamp & Co's 13F filing for Q1 2018, filed 11 May 2018.